丹诺苏马布作为治疗儿科高热血症的一种多中心经验
Annabelle Hobbs1,2, Rishi Nair2, Karissa Ludwig1,3,4
1Department of Endocrinology and Diabetes, Queensland Children's Hospital, South Brisbane 4101, Australia.
JBMR plus
|January 12, 2026
概括
德诺苏马布有效地治疗由各种原因引起的儿科高血症,包括恶性瘤. 这项研究表明,当其他治疗方法失败或双酸盐禁用时,它在儿童中具有安全性和有效性.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 在瘤学瘤学.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 丹诺苏马布是一种单克隆抗体向NF-κB合体 (RANKL) 的受体激活剂,已被确立用于成人高血症的治疗.
- 它在儿科高血症中的使用尚未得到充分记录,因此需要进一步调查.
研究的目的:
- 评估德诺苏马布在治疗儿科患者急性和慢性高血症中的疗效和安全性.
- 描述用denosumab管理的儿童的剂量,结果和不良事件.
主要方法:
- 一个多中心病例系列,涉及2个月至16岁的儿科患者,患有多种原因的高血症.
- 患者在其他疗法失败后或双酸盐禁用后,接受了多次剂量登苏马布 (0.125-0.5毫克/公斤).
- 密切监测血清水平和包括低血症在内的不良事件.
主要成果:
- 登诺苏马布成功地改善了所有儿科患者的高血症,峰值水平在3.29至5.04mmol/L之间.
- 两名患者在功能障碍恢复期间使用德诺苏马布作为桥梁到双酸盐治疗.
- 轻度低血症发生在两名患者身上,他们通过口服补充剂进行管理.
结论:
- 代诺苏马布是治疗儿科高血症的可行选择,特别是当其他干预措施无效或功能障碍禁忌双.
- 在儿童接受德诺苏马布治疗期间,密切监测血清的水平至关重要,可能需要多次剂量.
相关概念视频
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
239
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
239
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
249
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
249
01:29Drug Dosing: Infants and Children
241
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
241
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
185
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
185
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
201
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
201